Thérapeutique des mycoses profondes (à l'exception des aspergilloses et des fusarioses)

Revue Francaise des Laboratoires

Volumn 2001, Issue 332, 2001, Pages 23-30

  Léautez, Sophie ^a   Raffi, François ^a  

^a HÔTEL DIEU   (France)

Author keywords

Amphotericin B; Antifungal therapy; Candidiasis; Cryptococcal infections; Fluconazole; Flucytosine; Histoplasmosis; Itraconazole; Penicillium marneffel infections; Systemic fungal infections; Voriconazole

Indexed keywords

EID: 0035314999     PISSN: 03389898     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0338-9898(01)80124-4     Document Type: Article

References (58)

1. Al Arishi H., Frayha H.H., Kalloghlian A., Al Alaiyan S. Liposomal amphotericin B in neonates with invasive candidiasis. Am. J. Perinatol. 15:(11):1998;643-648.
2. Bradsher R.W. Histoplasmosis and blastomycosis. Clin. Infect. Dis. 22:1996;S102-S111. (Suppl. 2).
3. Breton P., Bani-Sadr F., Germaud P., Léautez S., Morin O., Raffi F. Une mycose pulmonaire rare : l'infection à Penicillium marneffei. Rev. Pneumol. Clin. 54:1998;85-87.
4. Butugan O., Sanchez T.G., Gonçalez F., Venosa A.R., Miniti A. Mucormycose rhinocérébrale : facteurs prédisposants, diagnostic, thérapeutique, complications et survie. Rev. Laryngol. Otol. Rhinol. 117:(1):1996;53-55.
5. Carillo-Munoz A.J., Quindos G., Tur C., Ruesga M.T., Miranda Y., del Valle O., et al. In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J. Antimicrob. Chemother. 44:1999;397-401.
6. Clancy C.J., Hong Nguyen M. Correlation between in vitro susceptibility determinated by E test and response to therapy with amphotericine B: results from a multicenter prospective study of candidemia. Antimicrob. Agents Chemother. 43:(5):1999;1289-1290.
7. Cobo Reinoso P., Aguado Garcia J.M., Lumbreras Bermejo C., Perez Vela J.L., Caballero Cubedo R., Sanz Sanz F., Noriega Rodriguez A.R. Tratamiento cos. ¿Anfotericina B o fluconazol? Estudio retrospectivo de 62 casos consecutivos. Rev. Clin. Esp. 197:1997;799-803.
8. Coukell A.J., Brogden R.N. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs. 55:(4):1998;585-612.
9. Devoisselle J.M. Les liposomes : aspects pharmaceutiques, comportements in vivo et réalités cliniques. La lettre du pharmacologue. 11:(10):1997;203-209.
10. Donowitz L.G., Owen Hendley J. Short-course amphotericin B therapy for candidemia in pediatric patients. Pediatrics. 95:(6):1995;888-891.
11. Dranitsaris G., Phillips P., Rotstein C., Puodziunas A., Shafran S., Garber G., et al. Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients. Pharmacoeconomics. 13:1998;509-518.
12. -1. Mycoses. 40:1997;267-277.
13. Edwards J.E. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis. 25:1997;43-59.
14. Eggiman P., Francioli P., Bille J., Schneider R., Wu M.M., Chapuis G., et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit. Care Med. 27:1999;1066-1072.
15. Fortun J., Lopez-San Roman A., Velasco J.J., Sanchez-Sousa A., de Vincente E., Nuno J., et al. Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 16:1997;314-318.
16. Giamarellou H., Antoniadou A. Epidemiology, diagnosis, and therapy of fungal infections in surgery. Infect. Control. Hosp. Epidemiol. 17:1996;558-564.
17. Goldman M., Johnson P.C., Sarosi G.A. Fungal pneumonias. The endemic mycoses. Clin. Chest Med. 20:1999;507-519.
18. Grant S.M., Clissold S.P. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 39:(6):1990;877-916.
19. Hiemenz J.W., Walsh T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22:1996;S133-S144. (Suppl. 2).
20. Hoban D.J., Zhanel G.G., Karlowsky J.A. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob. Agents Chemother. 43:1999;1463-1464.
21. Hong Nguyen M., Peacok J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:1996;617-623.
22. Hong Nguyen M., Clancy C.J., Yu V.L., Yu Y.C., Morris A.J., Snydman D.R., et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis. 177:1998;425-430.
23. van der Horst C.M., Saag M.S., Cloud G.A., Hamill R.J., Graybill J.R., Sobel J.D., et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency sydrome. N. Engl. J. Med. 337:1997;15-21.
24. Huttova M., Hartmanova I., Kralinsky K., Filka J., Uher J., Kurak J., et al. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr. Infect. Dis. J. 17:1998;1012-1015.
25. Imwidthaya P., Poungvarin N. Cryptococcosis in Aids. Postgrad. Med. J. 76:2000;85-88.
26. Jégo P., Le Strat A., Camus C., Gatel A., Grosbois B., Leblay R. Cryptococcose neuroméningée et leucémie lymphoïde chronique : à propos d'une obsrvation. Revue de la littérature. Rev. Med. Interne. 21:2000;83-85.
27. Kao A.S., Brandt M.E., Pruitt W.R., Conn L.A., Perkins B.A., Stephens D.S., et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1999;1164-1170.
28. Knapp S., Turnherr M., Dekan G., Willinger B., Stingl G., Rieger A. A case of HIV-associated cerebral histoplamosis successfully treated with fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 18:1999;658-661.
29. Kullberg B.J., de Pauw B.E. Therapy of invasive fungal infections. Neth. J. Med. 55:1999;118-127.
30. Launay O., Lortholary O., Bouges-Michel C., Jarrousse B., Bentata M., Guillevin L. Candidemia: a nosocomial complication in adults with late-stage Aids. Clin. Infect. Dis. 26:1998;1134-1141.
31. Lortholary O., Guillevin L., Dupont B., Drouhet e. Traitement des histoplasmoses et de la coccidioïdomycose. Med. Mal. Infect. 25:1995;63-73.
32. Lortholary O. Prise en charge des candidoses systémiques. Presse Med. 28:1999;1392-1394.
33. de Marie S. New developments in the diagnosis and management of invasive fungal infections. Haematologica. 85:2000;88-93.
34. Martin M.V. The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review. J. Antimicrob. Chemother. 44:1999;429-437.
35. Martino R., Subira M., Sureda A., Sierra J. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. J. Antimicrob. Chemother. 44:1999;569-572.
36. Menichetti F., Fiorio M., Tosti A., Gatti G., Pasticci M.B., Miletich F., et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with Aids. Clin. Infect. Dis. 22:1996;838-840.
37. Meyohas M.C., Meynard J.L., Bollens D., Roux P., Deluol A.M., Poirot J.L., et al. Treatment of non-meningeal cryptococcosis in patients with Aids. J. Infect. 33:1996;7-10.
38. Milatovic D., Voss A. Efficacy of fluconazole in the treatment of systemic fungal infections. Eur. J. Clin. Microbiol. Infect. Dis. 11:1992;395-402.
39. Milton Gaviria J., Grohskopf L.A., Barnes R., Root R.K. Successful treatment of rhinocerebral zygomycosis: a combined-strategy approach. Clin. Infect. Dis. 28:1999;160-161.
40. Moses A.E., Rahav G., Barenholz Y., Elidan J., Azaz B., Gillis S., et al. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion en three patients. Clin. Infect. Dis. 26:1998;1430-1433.
41. Pardal Refoyo J.L., Chocarro Martinez A., Brezmes Valdivieso M.F., Parra Perez C. Revision del tratamiento en la mucormicosis rinocerebral. Anales ORL Iber.-Amer. XXV:(1):1998;45-56.
42. de Pauw B.E., Meunier F. The challenge of invasive fungal infection. Chemotherapy. 45:1999;S1-S14. (Suppl. 1).
43. Petitjean O., Jacolot A., Tod M. Pharmacologie des antifongiques azolés systématiques. Med. Mal. Infect. 25:1995;14-26.
44. Phillips P., Shafran S., Garber G., Rotstein C., Smaill F., Fong I., et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur. J. Clin. Microbiol. Infect. Dis. 16:1997;337-345.
45. Powderly W.G. Recent advances in the management of cryptococcal meningitis in patients with Aids. Clin. Infect. Dis. 22:1996;S119-S123. (Suppl. 2).
46. Robinson P.A., Bauer M., Leal M.A.E., Evans S.G., Holtom P.D., Diamond D.A.M., et al. Early mycological treatment failure in Aids-associated cryptococcal meningitis. Clin. Infect. Dis. 28:1999;82-92.
47. Robinson R.F., Nahata M.C. A comparative review of conventional and lipid formulations of amphotericin B. J. Clin. Pharm. Ther. 24:1999;249-257.
48. Rowen J.L., Tate J.M. Management of neonatal candidiasis. Pediatr. Infect. Dis. J. 17:1998;1007-1011.
49. Saag M.S., Cloud G.A., Graybill J.R., Sobel J.D., Tuazon C.U., Johnson P.C., et al. A comparison of itraconazole versus fluconazole as maintenance therapy for Aids-associated meningitis. Clin. Infect. Dis. 28:1999;291-296.
50. Sirisanthana T., Supparatpinyo K., Perriens J., Nelson K.E. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 26:1998;1107-1110.
51. Stevens D.A., Diaz M., Negroni R., Montero-Gei F., Castro L.G.M., Sampaio S.A.P., et al. Safety evaluation of chronic fluconazole therapy. Chemotherapy. 43:1997;371-377.
52. Tumbarello M., Tacconelli E., de Gaetano Donati K., Morace G., Fadda G., Cauda R. HIV-infected subjects. Eur. J. Clin. Microbiol. Infect. Dis. 18:1999;478-483.
53. Uzun O., Anaissie E.J. Problems and controversies in the management of hematogenous candidiasis. Clin. Infect. Dis. 22:1996;S95-S101. (Suppl. 2).
54. Vanden Bossche H., Dromer F., Improvosi I., Lozano-Chiu M., Rex J.H., Sanglard D. Antifungal drug resistance in pathogenic fungi. Med. Mycol. 36:1998;S119-S128. (Suppl. 1).
55. Viscoli C., Castagnola E. Emerging fungal pathogens, during resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review. Int. J. Infect. Dis. 3:1999;109-118.
56. Viscoli C., Girmenia C., Marinus A., Collette L., Martino P., Vandercam B., et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fluid infection group (IFIG) of the european organization for research and treatment of cancer (EORTC). Clin. Infect. Dis. 28:1999;1071-1079.
57. Voss A., de Pauw B.E. High-dose fluconazole therapy in patients with severe fungal infections. Eur. J. Clin. Microbiol. Infect. Dis. 18:1999;165-174.
58. Walsh T.J., Finberg R.W., Arndt C., Heimenz J., Schwartz C., Bodensteiner D., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 340:1999;764-771.